Username:
Password:
Forgot Password?
Remember me
Decade: 2010-2010 2000-2009 1990-1999
Year: 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000
Issues: Vol. 38 December, 2002 p.S1-S31-Supplement 8 Vol. 38 No. 18 December, 2002 p.I-XII Vol. 38 November, 2002 p.S3-S188-Supplement 7 Vol. 38 No. 17 November, 2002 p.I-X Vol. 38 No. 16 November, 2002 p.I-II Vol. 38 No. 15 October, 2002 p.I-XVIII Vol. 38 September, 2002 p.EX1-EX14-Supplement 6 Vol. 38 September, 2002 p.S1-S87-Supplement 5 Vol. 38 No. 14 September, 2002 p.I-IV Vol. 38 No. 13 September, 2002 p.I-X Vol. 38 No. 12 August, 2002 p.I-IV Vol. 38 No. 11 July, 2002 p.I-IV Vol. 38 No. 10 July, 2002 p.I-IV Vol. 38 No. 9 June, 2002 p.I-VI Vol. 38 No. 8 May, 2002 p.I-VI Vol. 38 No. 7 May, 2002 p.I-VIII Vol. 38 March, 2002 p.I-II-Supplement 4 Vol. 38 March, 2002 p.S2-S179-Supplement 3 Vol. 38 No. 5 March, 2002 p.I-XIV Vol. 38 No. 4 March, 2002 p.I-XX Vol. 38 February, 2002 p.I-II-Supplement 2 Vol. 38 February, 2002 p.S3-S56-Supplement 1 Vol. 38 No. 6 p.I-X Vol. 38 No. 3 p.I-XIV Vol. 38 No. 2 p.I-XVI Vol. 38 No. 1 January, 2002 p.I-XVI
Search Within This Issue
5 Articles:
Abstract: ZD0473 is new platinum agent that was rationally designed to circumvent platinum resistance and reduce the potential for nephro- and neurotoxicity. This Phase I dose-escalating study investi...
Abstract: Resistance to platinum-containing regimens can develop in many women with ovarian cancer and may lead to relapse in > 80% of patients. ZD0473 is a new-generation platinum agent that, in p...
Abstract: Three open-label, non-comparative, multicentre Phase II trials have examined the efficacy and tolerability of ZD0473 as first- and second-line therapy in non-small-cell lung cancer (NSCLC) p...
Abstract: A phase II, open-label, non-comparative, multicentre trial of the platinum analogue ZD0473 as second-line therapy for pleural mesothelioma has been completed. The objectives were to evaluate...
Abstract: Platinum-based combination chemotherapy regimens are the mainstay of current treatments for advanced solid malignancies. Preclinical in vitro studies have shown synergism with ZD0473 in comb...
